Baseline demographic details of patients recruited in the study
| Parameter | Result |
| Eligible patients | 379 |
| Sex (N (%)) | |
| Female | 130 (34.3%) |
| Male | 249 (65.7%) |
| Age | |
| Mean±SD (years) | 69.7±9.0 |
| <65 years (N (%)) | 95 (25.1%) |
| 65–75 years (N (%)) | 154 (40.6%) |
| ≥75 years (N (%)) | 130 (34.3%) |
| Region (N (%)) | |
| South Korea | 325 (85.8%) |
| All other countries | 54 (14.2%) |
| CHA2DS2-VASc stroke risk score | |
| Mean±SD | 3.1±1.4 |
| Low risk (score=0) | 5 (1.3%) |
| Intermediate risk (score=1) | 43 (11.3%) |
| High risk (score ≥2) | 331 (87.3%) |
| HAS-BLED bleeding risk score | |
| Mean±SD | 1.8±1.1 |
| Low risk (score <3) | 291 (76.8%) |
| High risk (score ≥3) | 88 (23.2%) |
| Creatinine clearance (mL/min) | |
| Mean±SD | 68.1±23.1 |
| <50 mL/min | 64 (16.9%) |
| 50 to <80 mL/min | 126 (33.2%) |
| ≥80 mL/min | 69 (18.2%) |
| Not available | 120 (31.7%) |
| No of patients with at least one prespecified concomitant disease (N (%)) | 279 (73.6%) |
| Concomitant diseases (N (%))* | |
| Hypertension | 164 (43.3%) |
| Hyperlipidaemia | 128 (33.8%) |
| Diabetes mellitus (type 1 or 2) | 68 (17.9%) |
| Congestive heart failure | 65 (17.2%) |
| Stroke | 35 (9.2%) |
| Concomitant therapies (N (%)) | |
| Verapamil | 4 (1.1%) |
| Amiodarone | 28 (7.4%) |
| Antithrombotic agents | 58 (15.3%) |
| NSAIDs | 7 (1.8%) |
| Type of hospital or practice (N (%)) | |
| Public | 171 (45.1%) |
| Private | 200 (52.8%) |
| Other | 8 (2.1%) |
*Most frequent five are listed.
CHA2DS2-VASc, congestive heart failure, hypertension, age ≥75 years (double score), diabetes, stroke or transient ischemic attack (TIA; double score), vascular disease, age 65–74 years, sex class; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalised ratio, elderly (> 65 years), drugs/alcohol concomitantly; NSAIDs, non-steroidal anti-inflammatory drugs.